Evogene (NASDAQ:EVGN) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Evogene (NASDAQ:EVGN) in a report published on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Evogene Stock Performance

Shares of EVGN stock opened at $0.71 on Thursday. The stock has a market capitalization of $29.27 million, a price-to-earnings ratio of -1.34 and a beta of 1.47. Evogene has a one year low of $0.45 and a one year high of $1.44. The company’s 50-day simple moving average is $0.78 and its 200-day simple moving average is $0.75.

Evogene (NASDAQ:EVGN) last posted its quarterly earnings results on Thursday, March 7th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. The company had revenue of $0.58 million for the quarter, compared to the consensus estimate of $1.73 million. Evogene had a negative net margin of 423.39% and a negative return on equity of 76.93%. During the same period last year, the firm posted ($0.07) EPS.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets lifted its stake in Evogene Ltd. (NASDAQ:EVGN) by 30.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors and hedge funds.

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.